파이프라인
Platform | Project | Theraqeutics | Indication | R&D | Preclinical | Phase I | Phase II | NDA |
---|---|---|---|---|---|---|---|---|
TIL | NEOG-100 | TIL (Tumor Infiltrating Lymphocyte) |
Solid tumor (TNBC, NSCLC) |
|
||||
TCR-T | NEOG-3000 | Shared antigen specfic TCR engineered T (TCR-T) cell |
Solid tumor |
|
||||
TCR-T | NEOG-4000 | Private Neoantigen specific TCR engineered T (TCR-T) cell |
Solid tumor |
|
||||
TCR-T | Transposon system | Gene engineering system |
|
-
NEOG-100
-
Theraqeutics
TIL
(Tumor Infiltrating Lymphocyte) -
Indication
Solid tumor
(TNBC, NSCLC)
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
Transposon system
-
Theraqeutics
Gene engineering system -
Indication
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-3000
-
Theraqeutics
Shared antigen specfic
TCR engineered T (TCR-T) cell -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-
-
NEOG-4000
-
Theraqeutics
Private Neoantigen specific
TCR engineered T (TCR-T) cell -
Indication
Solid tumor
- R&D
- Preclinical
- Phase I
- Phase II
- NDA
-